External Validation Readiness
Internal Evidence, Clinical Governance, and Readiness for External Validation.
NVOX is built as a clinician-integrated, multimodal Clinical Decision Support framework for ADHD assessment. The current evidence position reflects an operationally implemented platform with a locked analytical cohort, a structured multimodal workflow, clinical governance, quality controls, and a defined roadmap for external validation.
The public evidence shows an organized internal evidence base: real-world workflow implementation, multiple assessment layers collected across completed evaluations, clinical review, clinical and medical oversight, and clear interpretation boundaries.
Current Evidence Position
.svg)
An Implemented, Governed Platform Ready for the Next Stage of External Validation
The current public evidence supports NVOX as an operationally implemented, multimodal, quality-governed clinical platform designed to organize ADHD assessment evidence and support clinician-led review.
NVOX presents its evidence position as External Validation Readiness: an operationally implemented, literature-informed, quality-governed, clinician-reviewed platform with internal operational evidence and a defined external validation roadmap.
The internal evidence base is a structured and organized foundation for the next stage: independent, protocol-driven external validation.
The current framework includes:
Operational implementation of a
structured clinical workflow
.svg)
Collection and organization of multiple
information layers
.svg)
Separation of evidence sources
.svg)
Documentation of data quality and interpretability
.svg)
Clinical review and report authorization
.svg)
Clinical and medical oversight
.svg)
Governance, quality controls, and claims boundaries
A defined roadmap for external validation
Public Evidence Snapshot
The Public Evidence Snapshot is Based on a Locked Analytical Cohort
The Evidence area is designed for clinicians, informed families, institutional stakeholders, research partners, digital health reviewers, and professional readers who want to understand how NVOX is built, what currently supports the framework, and what still requires further external validation.
This section presents the clinical architecture behind NVOX, its evidence layers, claims boundaries, internal operational evidence, clinical oversight model, platform limitations, and roadmap for external validation.
Initial workflow population
1,043
Cases
Pediatric and adolescent evaluations
503
Evaluations, Ages 8 to 17
Cases excluded before final analysis
29
Cases
Final Analytical Cohort
1,014
Completed Evaluations
Adult evaluations
511
Evaluations, Ages 18 to 57
How to read these numbers
The initial workflow population included 1,043 cases within the relevant evidence window. After a 29-case exclusion funnel, the final locked analytical cohort included 1,014 completed evaluations.
The number 1,014 is the central public denominator for this release. It represents the final cohort used for the public evidence snapshot and should be interpreted within the documented cohort window and methodological boundaries.
Core Multimodal Coverage
Nearly All Evaluations in the Final Cohort Included Core Multimodal Coverage.
.svg)
Core multimodal coverage was achieved in 1,012 of 1,014 completed evaluations. This reflects completion of core clinical data, developmental and functional assessment, and usable dCPT capture. NVOX Labs research analytics are excluded from this measure.
Depending on the case and pathway, multimodal coverage may include:
Structured questionnaires
Collateral input from relevant people
Existing documents
Assessment tasks
Performance measures
Behavioral context
Signal quality and interpretability context
Clinical review
Clinical report workflow
This is an operational measure of workflow coverage and evidence completeness.
It is not presented as a standalone diagnostic accuracy measure.
Why External Validation Matters
External Validation Readiness is an Advanced Evidence Stage, Not an Endpoint Claim.
NVOX has an implemented workflow, a locked cohort, an internal evidence base, clinical governance, and a roadmap for external research. The next stage is planned external validation using a defined protocol, a clear study population, an independent or semi-independent reference process, subgroup analysis, and transparent reporting.
This measure helps characterize how the dCPT component behaves within the broader NVOX workflow. It is presented as internal workflow monitoring, not as independent diagnostic accuracy and not as a standalone dCPT validation result.
Its value is in showing operational consistency within the NVOX framework while preserving the correct interpretation: platform components support clinical review; they do not replace it.
External Validation Roadmap
What the Next Stage Should Examine
A rigorous external validation program should examine not only diagnostic agreement against an appropriate reference process, but also the broader clinical value of the assessment workflow itself.
Future validation work may include:
Full-platform external validation
External evaluation of the complete NVOX workflow against an independent or semi-independent reference process.
Profile reliability and clinical utility
Assessment of stability, usability, informant mapping, and clinical value of the structured clinical profile.
Objective task contribution
Evaluation of how performance-based assessment tasks contribute to the overall assessment workflow, while minimizing incorporation bias.
Response validity and performance authenticity
Assessment of response consistency, performance authenticity, motivation effects, coached responding, and identity assurance when relevant.
NVOX Labs Research Analytics
Future research may evaluate the reliability, fairness, and research utility of NCBA and WAVE. These investigational modules are not incorporated into NVOX diagnostic determinations.
Research Analytics Robustness
Future research may evaluate the stability, interpretability, and fairness of behavioral, oculomotor, and voice-based NVOX Labs research analytics across devices, recording conditions, languages, and relevant subgroups.
Access, efficiency, and underserved-population impact
Evaluation of whether NVOX can help improve access to high-quality ADHD assessment for people and families who face barriers to traditional evaluation, including cost, geographic distance, limited specialist availability, school-navigation barriers, system delays, or other access challenges.
Governance and clinical safety audit
Review of clinical governance, safety escalation, access controls, clinician override, quality controls, and lifecycle management.
Human-factors research
Study of comfort, cooperation, stress reduction, completion rates, user experience, and the role of guided remote assessment in supporting engagement.
Validation Beyond a Single Number
The Quality of an ADHD Assessment is Not Captured by One Metric Alone
For NVOX, validation is not limited to whether a clinician-reviewed final interpretation aligns with an external reference process. That question is important, but it is only one part of the evidence picture.
NVOX should also be evaluated for its ability to improve the quality, completeness, and usability of the assessment record itself: how information is collected, how conflicting evidence is surfaced, how clinical reasoning is supported, how clearly findings are explained, and how useful the final report is for patients, families, clinicians, and institutions.
Future validation work may include:
Clinical evidence completeness
Whether NVOX captures and organizes the information clinicians need to conduct a responsible ADHD assessment.
Clinical reasoning transparency
Whether clinicians can understand why evidence converges, diverges, or requires further interpretation.
Alternative explanations and co-occurring concerns
Whether the workflow helps surface relevant information related to sleep, anxiety, mood, learning, language, trauma, medical factors, or other co-occurring clinical concerns.
Clinician utility
Whether NVOX improves clinician confidence, documentation quality, contradiction detection, review efficiency, and clinical autonomy.
Patient and family understanding
Whether the feedback process and report help patients and families better understand the findings, functional meaning, and appropriate next steps.
Report usefulness
Whether reports are clear, functional, appropriately bounded, and useful for conversations with schools, colleges, workplaces, testing bodies, or other professionals, without presenting the report as a legal or institutional eligibility decision.
Research Analytics Evaluation
Whether investigational behavioral, oculomotor, and voice-related research analytics are stable, interpretable, and fair across relevant subgroups. These modules remain separate from NVOX diagnostic determinations.
Access and efficiency impact
Whether NVOX can support faster, more efficient access to high-quality ADHD assessment for people and families who may otherwise face cost, distance, availability, or system-level barriers.
Workflow quality and documented governance
Whether the review process, quality controls, access permissions, escalation pathways, clinician override, and lifecycle governance operate consistently, safely, and transparently.
Standards and Regulatory-Facing Readiness
Built to Support Professional and Regulatory-Facing Review
NVOX is building its evidence, governance, and documentation program to support future regulatory-facing review where appropriate, including analysis under FDA Clinical Decision Support guidance and other applicable digital health frameworks.
The public evidence release is not a certification claim, regulatory clearance document, or completed external validation report. It is a professional evidence and readiness document intended to support structured review, responsible interpretation, and future external validation planning.
Controlled Review for Qualified Reviewers
Additional Materials are Available Through a Controlled Professional Review Process
Public Release v1.2 presents a professional public version of the NVOX evidence framework. Additional technical, numerical, security, and implementation materials are not presented to the general public.
Controlled access to additional materials may be considered for qualified reviewers only, such as research institutions, academic partners, clinical or institutional reviewers, digital health technology reviewers, regulatory advisors, or similar professional review bodies, under appropriate confidentiality and review arrangements.
Institutional or Research Review Inquiry →